Telix Pharmaceuticals (ASX:TLX) has announced the appointment of a CEO for its Americas business and dosed the final patient and completed recruitment into the pivotal Phase 3 study, ZIRCON.
Kevin Richardson has been appointed CEO of Telix Americas.
Mr Richardson brings 25 years of experience in the healthcare industry. Most recently, he was the chief operating officer of UroShape Medical, a technology company that has developed and successfully commercialised a medical device for a large, undertreated segment in the women's health market. He previously spent seven years in the Americas division of Australian radiopharmaceutical Sirtex Medical and held senior roles with St Jude Medical and Boston Scientific.
Telix Pharmaceuticals CEO and managing director said, "Kevin brings a new depth of commercialisation, sales and marketing experience to our U.S. operations along with a solid understanding of the intricacies of the radiopharmaceutical industry. His experience will be extremely valuable as we maximize the opportunity of our first commercial product and as we prepare to bring additional products to market. I have confidence that Kevin brings the leadership skills and track record that will drive our growth in the region."
Mr Richardson added, "I'm very excited to take on the role of CEO for Telix Americas. Telix has quickly established itself as a highly regarded global leader and innovator in radiopharmaceuticals. I look forward to bringing my experience in scaling up growth-stage companies to ensure Telix is able to translate its strong start as a commercial-stage company into long-term success across the United States, Canada and South America."
The company also announced the final patient and completed recruitment into the pivotal Phase 3 study ZIRCON of its investigational renal cancer imaging agent TLX250-CDx.
The company, which said the global study has dosed 300 patients to date, added that the investigational agent may provide a non-invasive method to aid in the diagnosis and staging of clear cell renal cell cancer and the identification of metastatic disease through whole-body imaging.